ERBB2 and ductal breast carcinoma in situ: Thus, whether systemic therapies other than ET are needed to prevent distant metastasis and improve breast cancer mortality in HR‐positive patients and in HR‐negative or HER‐2‐positive patients with DCIS is unclear.